A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease | Center for Neurodegeneration and Translational Neuroscience (CNTN)

Cummings JL, Cohen S, van Dyck CH, Brody M, Curtis C, Cho W

Neurology

April 2018

← Back to Publications